Pfizer Inc. (NYSE:PFE) Shares Sold by Investment Research & Advisory Group Inc.

Investment Research & Advisory Group Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 46.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 37,291 shares of the biopharmaceutical company’s stock after selling 31,710 shares during the quarter. Investment Research & Advisory Group Inc.’s holdings in Pfizer were worth $1,074,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in PFE. Worth Asset Management LLC purchased a new position in shares of Pfizer during the first quarter worth approximately $29,000. Briaud Financial Planning Inc acquired a new stake in Pfizer in the third quarter valued at $30,000. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. purchased a new position in shares of Pfizer in the third quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC increased its position in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Friday, March 1st. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Truist Financial dropped their price target on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

Shares of PFE stock traded up $0.15 during trading on Wednesday, hitting $27.74. The company’s stock had a trading volume of 16,861,972 shares, compared to its average volume of 43,564,594. The company has a market cap of $157.08 billion, a PE ratio of 77.14, a P/E/G ratio of 1.23 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The business has a fifty day moving average of $27.48 and a 200-day moving average of $29.52. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the prior year, the business earned $1.14 earnings per share. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.